EUVIMEDEUVIMED entdecken
Open Access

ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications

Shuqi Wang iD, Peter F Thall, Kentaro Takeda iD, Ying Yuan iD

Biometrics · 2024

DOI: 10.1093/biomtc/ujae105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2024. Verfasst von Shuqi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Bayes Theorem, Dose-Response Relationship, Drug, Randomized Controlled Trials as Topic, Maximum Tolerated Dose. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimizing doses for multiple indications is challenging. The pooled approach of finding a single optimal biological dose (OBD) for all indications ignores that dose-response or dose-toxicity curves may differ between indications, resulting in varying OBDs. Conversely, indication-specific dose optimization often requires a large sample size. To address this challenge, we propose a Randomized two-stage basket trial design that Optimizes doses in Multiple Indications (ROMI). In stage 1, for each indication, response and toxicity are evaluated for a high dose, which may be a previously obtained maximum tolerated dose, with a rule that stops accrual to indications where the high dose is unsafe or ineffective. Indications not terminated proceed to stage 2, where patients are randomized between the high dose and a specified lower dose. A latent-cluster Bayesian hierarchical model is employed to borrow information between indications, while considering the potential heterogeneity of OBD across indications. Indication-specific utilities are used to quantify response-toxicity trade-offs. At the end of stage 2, for each indication with at least one acceptable dose, the dose with highest posterior mean utility is selected as optimal. Two versions of ROMI are presented, one using only stage 2 data for dose optimization and the other optimizing doses using data from both stages. Simulations show that both versions have desirable operating characteristics compared to designs that either ignore indications or optimize dose independently for each indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bayes TheoremDose-Response Relationship, DrugRandomized Controlled Trials as TopicMaximum Tolerated DoseHumansResearch DesignComputer SimulationSample SizeModels, StatisticalBiometry

Stichwörter der Autor:innen

Bayesian hierarchical modelProject Optimusdose optimizationmultiple indicationsrandomizationutility

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Astellas Pharma Global Development Inc., Northbrook, IL 60062, United States.

ORCID-Profile: Shuqi Wang, Kentaro Takeda, Ying Yuan

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Wang, S., Thall, P. F., Takeda, K., & Yuan, Y. (2024). ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics. https://doi.org/10.1093/biomtc/ujae105

Vancouver

Wang S, Thall PF, Takeda K, Yuan Y. ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics. 2024. doi:10.1093/biomtc/ujae105

BibTeX
@article{Wang2024,
  author = {Wang, Shuqi and Thall, Peter F and Takeda, Kentaro and Yuan, Ying},
  title = {ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications},
  journal = {Biometrics},
  year = {2024},
  doi = {10.1093/biomtc/ujae105}
}
Kostenlos starten →